MedTrace Logo

Study of NTB-928 in R/R OC

NCT07690189 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-08-20

No results posted yet for this study

Summary

The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the body, and how the immune system reacts to it. The study will also look for early signs of anti-cancer activity of NTB-928. The main questions the study aims to answer are:

* What side effects do participants experience when receiving NTB-928, including side effects that limit how much of it can be safely given?
* How is NTB-928 processed by the body at different dose levels?
* Does the immune system react to NTB-928 during treatment?
* What dose of NTB-928 can be given safely that shows early signs of activity against ovarian cancer?

Conditions

  • Relapsed/Refractory Ovarian Carcinoma

Interventions

DRUG

NTB-928

NTB-928 is an investigational study drug administered as an intravenous infusion.

Sponsors & Collaborators

  • TeneoSeven, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-29
Primary Completion
2028-06-30
Completion
2029-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07690189 on ClinicalTrials.gov